PreveCeutical Medical (PRVCF) Stock Price, News & Analysis

Company Overview

PreveCeutical Medical Inc. is a biotechnology company focused on developing non-opioid therapies that target the endocannabinoid system through advanced translational medicine. The company leverages proprietary research in prebiotic and synthetic bioactive compounds to create drug candidates and wellness formulations aimed at addressing metabolic, inflammatory and neurodegenerative disorders. PreveCeutical’s science-driven approach emphasizes collaboration with leading academic institutions to translate laboratory discoveries into therapeutic solutions.

Central to PreveCeutical’s development pipeline is PREV-IX7, a prebiotic drug candidate designed to modulate the gut microbiome for treatment of metabolic syndrome and related endocrine imbalances. The company also holds intellectual property on a novel synthetic cannabinoid analog intended to alleviate symptoms of fibromyalgia and irritable bowel syndrome. In parallel, PreveCeutical has advanced full-spectrum CBGa hemp extract formulations for consumer health and wellness products, supported by preclinical studies to establish safety and efficacy profiles.

Founded in 2016 and headquartered in Brisbane, Australia, PreveCeutical maintains an operational presence in North America to facilitate commercialization activities. Under the leadership of Founder and Chief Executive Officer Konstantin Dobrovolski, the company partners with organizations such as the University of Queensland to drive its research and development agenda. PreveCeutical continues to pursue regulatory milestones and strategic alliances aimed at bringing its innovative therapies and wellness products to market.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.03
• 52-Week Range: $0.01 to $0.03
• Volume: 1,000 shs
• Average Volume: 92,817 shs
• Market Capitalization: $12.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PRVCF Stock Analysis - Frequently Asked Questions

How have PRVCF shares performed this year?

PreveCeutical Medical's stock was trading at $0.0184 at the beginning of 2025. Since then, PRVCF stock has increased by 18.5% and is now trading at $0.0218.

How do I buy shares of PreveCeutical Medical?

Shares of PRVCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PRVCF
• CIK: N/A
• Web: www.preveceutical.com
• Phone: (604) 416-7777
• Fax: 778-945-6290
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$860 thousand
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -821.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.01
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.01) per share
• Price / Book: -2.29

Miscellaneous

• Outstanding Shares: 570,650,000
• Free Float: N/A
• Market Cap: $13.07 million
• Optionable: Not Optionable
• Beta: 0.49